Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Mar 26, 2025; 17(3): 102893
Published online Mar 26, 2025. doi: 10.4330/wjc.v17.i3.102893
Shedding light on the effects of sodium-glucose cotransporter 2 inhibitors in the early stages of heart failure
Luigi Falco, Emilio Di Lorenzo, Daniele Masarone
Luigi Falco, Emilio Di Lorenzo, Daniele Masarone, Department of Cardiology, AORN dei Colli Monaldi Hospital, Naples 80131, Italy
Author contributions: Falco L and Masarone D contributed to conceptualization, and writing and reviewing; Di Lorenzo E and Masarone D contributed to visualization and supervision; and all the authors edited the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Daniele Masarone, MD, PhD, Department of Cardiology, AORN dei Colli Monaldi Hospital, Via Leonardi Bianchi, Naples 80131, Italy. danielemasarone@gmail.com
Received: November 10, 2024
Revised: January 5, 2025
Accepted: February 27, 2025
Published online: March 26, 2025
Processing time: 140 Days and 13.1 Hours
Core Tip

Core Tip: Despite the advances in pharmacological therapy of symptomatic heart failure (HF), evidence for asymptomatic patients is poor, and sodium-glucose cotransporter 2 inhibitors are currently not recommended in pre-HF patients without diabetes. Therefore, further studies are needed to provide efficacy and mechanistic insights in patients in early stages of HF, especially considering the significant clinical and financial implications of treating HF at the beginning of its natural history.